Forte Biosciences (FBRX) Net Cash Flow (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Net Cash Flow data on file, last reported at -$18.7 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 179.31% year-over-year to -$18.7 million in Q1 2026; TTM through Mar 2026 was $12.4 million, a 19.82% decrease from a year earlier, with the FY2025 full-year figure at $54.7 million, up 467.55% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$18.7 million, down from -$16.5 million in the prior quarter.
• Over the last five years, Net Cash Flow for FBRX reached as high as $60.3 million in Q2 2025 and fell as low as -$18.7 million in Q1 2026.
• Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of -$5.2 million in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 1113.93% in 2025 and fell as far as 380.14% in 2025.
• Year by year, Net Cash Flow stood at -$2.9 million in 2022, then slumped by 207.33% to -$9.1 million in 2023, then soared by 164.91% to $5.9 million in 2024, then plunged by 380.14% to -$16.5 million in 2025, then fell by 13.66% to -$18.7 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$18.7 million in Q1 2026, -$16.5 million in Q4 2025, and -$12.7 million in Q3 2025.